Gilead Reduces Prices for Viread® and Truvada® in the Developing World
Advertisement
Gilead Sciences, Inc. announced a significant price reduction for Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) made available through the company's Access Program in the developing world. Both once-a-day antiretroviral medications for HIV are available at no-profit prices in 97 developing countries around the world through this program.
The price decreases announced are due to increased economies of scale, production at a new plant in the Bahamas that manufactures active pharmaceutical ingredient for both Viread and Truvada, and continued improvements in the manufacturing process. As a result of these changes, Viread and Truvada are now priced at US$17.00 and US$26.25 for a 30-day supply, or $0.57 and $0.87 per day, respectively, for private and public programs treating people with HIV/AIDS in the 97 nations of the program. The new prices represent approximately a 31 percent and 12 percent reduction in the no-profit prices for Viread and Truvada, respectively.
Most read news
Organizations
Other news from the department research and development
These products might interest you
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Flawless Protection for the Car - How Coatings Become Scratch Resistant
Evonik to expand capacity for polyamide 12 powder in Marl - Investment volume in the mid double-digit million euro range
BASF, Cargill and Novozymes target commercial bio-based acrylic acid process - Key raw material for the production of bio-based superabsorbents for baby diapers
UCI chemistry center awarded $20 million from NSF - Scientists seek to video the inner workings of single molecules
ALTANA completes acquisition of USBP
WACKER POLYMERS to Raise Prices For Vinyl Acetate-Based Dispersions in the Americas
Investment boosts SpheriTech’s growth
BASF Panama S.A. - Panama-Stadt, Panama
Analytik Jena Wins Major Order in Poland
Plasma_arc_waste_disposal
On the Death of Polymers - Revisiting Termination Rate Coefficients in Radical Homopolymerization